TY - JOUR
T1 - Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies
T2 - The immune response to antibody therapeutics preferentially targets the antigen-binding site
AU - van Schie, Karin A.
AU - Kruithof, Simone
AU - van Schouwenburg, Pauline A.
AU - Vennegoor, Anke
AU - Killestein, Joep
AU - Wolbink, Gertjan
AU - Rispens, Theo
PY - 2017/3/1
Y1 - 2017/3/1
N2 - This study shows that the immune response towards natalizumab, an IgG4 antibody targeting alpha4-integrins, is directed towards the antigen binding site of the drug. This extends previous observations for TNF inhibitors, suggesting that antibodies towards therapeutic antibodies may be inherently neutralizing
AB - This study shows that the immune response towards natalizumab, an IgG4 antibody targeting alpha4-integrins, is directed towards the antigen binding site of the drug. This extends previous observations for TNF inhibitors, suggesting that antibodies towards therapeutic antibodies may be inherently neutralizing
UR - http://www.scopus.com/inward/record.url?scp=85006263551&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jaci.2016.09.014
DO - https://doi.org/10.1016/j.jaci.2016.09.014
M3 - Article
C2 - 27717666
SN - 0091-6749
VL - 139
SP - 1035-1037.e6
JO - Journal of allergy and clinical immunology
JF - Journal of allergy and clinical immunology
IS - 3
ER -